2b | IPF | ~120K in US ~110K in EU5 |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for radiation induced fibrosis; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (IPF-ILDs) and exploring LYT-100 in myocardial and other organ system fibrosis.
1/2 | Solid tumors | ~82K/year U.S. (Bladder cancer) |
Fully human IgG4 monoclonal antibody, or mAb, designed to inhibit the activity of galectin-9, an immunomodulatory molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells. We are developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. We are also developing LYT-200 for the treatment of hematological malignancies, such as acute myeloid leukemia (AML).
1 | Depression, anxiety & related indications |
Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety and depression. Allopregnanolone is a positive allosteric modulator of GABAA receptors that has therapeutic potential across a wide range of neurological conditions, including depression and anxiety disorders, though its therapeutic application has been limited due to high first pass metabolism. Our Glyph platform reversibly links a drug to a dietary fat molecule, creating a novel prodrug. We believe this technology has the potential to provide a broadly applicable means of enhancing the bioavailability of certain orally administered drugs that would otherwise be limited by first-pass liver metabolism.
Preclinical | Epilepsies & other neurological indications |
Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.
Phase completed | Phase in progress |
Advancing transformative medicines for people living with psychiatric and neurological conditions
Pioneering the development of cognitive treatments through game-changing technologies
Advancing a novel category of treatments for weight management and gut related chronic diseases
Engineering hematopoietic stem cells to enable targeted therapies post-transplant
Pioneering a new category of oral therapies based on defined bacterial consortia
Developing a voice-based technology platform to detect changes of health conditions
Engineering hydrogels to enable the oral administration of biologics